Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Adenovirus vector VRX-011 has enhanced specific oncolytic efficacy and restriction in primary cells

June 11, 2004

Orphan drug status for MDX-101

June 11, 2004

Promising phase II results for MDX-060 in Hodgkin's disease

June 11, 2004

Antitumor effects found with AP-12009 in recurrent high-grade gliomas

June 10, 2004

Merck KGaA to return Theratope rights to Biomira

June 9, 2004

Therion cleared to conduct phase III pancreatic cancer trial of Panvac-VF

June 4, 2004

Merck KGaA presents bispecific anti-ErbB antibodies for cancer therapy

June 2, 2004

European orphan drug status for HuMax-CD4 in CTCL

May 28, 2004

Favrille receives SPA from FDA for FavID

May 25, 2004

Biomira and Inno-centre Alberta to create spin-off company to develop L-IL-2 technology

May 25, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...